HIMA device submissions workshop
This article was originally published in The Gray Sheet
July 27-28 meeting in Washington, D.C. will include presentations by Office of Device Evaluation Director Susan Alpert on FDA's implementation of "least burdensome" requirements and by the device center's Jim Norman on the recent dispute resolution guidance. An opening speaker, scheduled to discuss Commissioner Jane Henney's priorities, international harmonization and user fees, has yet to be announced
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.